Oruka Therapeutics, Inc. (NASDAQ:ORKA) Stock Has Average Target Price of $128.91 According to Analysts

Key Points

• Analysts maintain a “Moderate Buy” consensus on Oruka Therapeutics, with 10 buy ratings and one sell rating; the average 12-month price target is $128.91 versus the stock’s recent price of $79.50.
• ORKA shares have pulled back 0.8% and recently reported a quarterly loss of $0.55 per share, missing the $0.51 consensus estimate. The stock trades between a 12-month range of $20.25 and $115.51.
• Institutional ownership is substantial at 56.44%, including a new $474.9 million BlackRock stake, while insiders sold 147,950 shares worth $13.6 million over the past 90 days.

Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eleven brokerages that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and ten have given a buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $128.91.

A number of equities analysts have recently commented on ORKA shares. Wall Street Zen cut Oruka Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday, August 16th. UBS Group increased their price target on Oruka Therapeutics from $100.00 to $130.00 and gave the company a "buy" rating in a report on Wednesday, July 1st. Piper Sandler restated an "overweight" rating on shares of Oruka Therapeutics in a research report on Wednesday. Weiss Ratings raised shares of Oruka Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday, July 15th. Finally, Mizuho set a $120.00 price objective on shares of Oruka Therapeutics in a research report on Thursday, September 3rd.

Insider Buying and Selling

In related news, CEO Lawrence Klein sold 75,000 shares of Oruka Therapeutics stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $91.83, for a total transaction of $6,887,250.00. Following the completion of the transaction, the chief executive officer directly owned 925,580 shares of the company's stock, valued at approximately $84,996,011.40. The trade was a 7.50% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Arjun Agarwal sold 10,000 shares of the company's stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $106.66, for a total transaction of $1,066,600.00. Following the transaction, the senior vice president owned 15,312 shares in the company, valued at $1,633,177.92. The trade was a 39.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 147,950 shares of company stock valued at $13,619,306. Company insiders own 23.49% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of ORKA. BlackRock Inc. bought a new stake in Oruka Therapeutics during the 2nd quarter valued at about $474,916,000. Remedium Capital Partners LLC grew its stake in Oruka Therapeutics by 0.9% in the first quarter. Remedium Capital Partners LLC now owns 1,565,661 shares of the company's stock worth $76,796,000 after purchasing an additional 13,247 shares in the last quarter. Perceptive Advisors LLC increased its holdings in Oruka Therapeutics by 16.4% during the 4th quarter. Perceptive Advisors LLC now owns 1,476,501 shares of the company's stock worth $44,753,000 after purchasing an additional 208,480 shares during the period. Jupiter Topco LLC purchased a new position in Oruka Therapeutics during the 2nd quarter worth $130,968,000. Finally, Avidity Partners Management LP raised its position in Oruka Therapeutics by 15.1% during the 1st quarter. Avidity Partners Management LP now owns 760,424 shares of the company's stock valued at $37,299,000 after purchasing an additional 100,000 shares in the last quarter. Hedge funds and other institutional investors own 56.44% of the company's stock.

Oruka Therapeutics Trading Down 0.8%

Shares of NASDAQ ORKA opened at $79.50 on Thursday. The firm's 50-day moving average price is $95.27 and its 200-day moving average price is $78.57. The stock has a market capitalization of $5.26 billion, a price-to-earnings ratio of -39.16 and a beta of -0.37. Oruka Therapeutics has a 12-month low of $20.25 and a 12-month high of $115.51.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.04). On average, equities analysts predict that Oruka Therapeutics will post -2.42 EPS for the current fiscal year.

About Oruka Therapeutics

Oruka Therapeutics, Inc NASDAQ: ORKA is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company's approach is designed to extend the duration of treatment and potentially reduce the frequency of dosing for patients with chronic inflammatory conditions.

Oruka's pipeline includes ORKA-001 and ORKA-002, next-generation monoclonal antibodies targeting interleukin-23 (IL-23), a cytokine involved in several autoimmune and inflammatory diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.